By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mologen AG 

P.O. Box 332140

Berlin    D - 14180  Germany
Phone: 49-0-30-857-576-0 Fax: 49-0-30-857-576-50



Gene Therapy

Company News
Mologen (MOLGF.PK) Release: Grant To Collaboration Partner For Combination Study In HIV With Lead Product Lefitolimod 1/10/2017 11:08:43 AM
Mologen (MOLGF.PK) Presents First Anti-Tumor Data Of The Product Candidate And TLR9 Agonist EnanDIM In A Murine Tumor Model 9/12/2016 11:13:40 AM
Mologen (MOLGF.PK): First Patient Recruited In Combination Study With Lefitolimod And Yervoy 7/13/2016 10:39:00 AM
Mologen (MOLGF.PK): First Patients Enrolled In Extension Phase Of The HIV Study TEACH 6/28/2016 8:39:37 AM
Mologen (MOLGF.PK) Restructures, Pushes Immunology Program, Shelves Renal Cancer Vaccine 6/9/2016 7:45:30 AM
Mologen AG (MOLGF.PK): Further Progress In Clinical Studies With Lead Product Lefitolimod In Q1 2016 5/12/2016 12:06:11 PM
Mologen AG (MOLGF.PK) To Present Next Generation Of TLR9 Agonists At ASGCT 2016 5/4/2016 10:25:23 AM
Mologen AG (MOLGF.PK): All Key Milestones Achieved In 2015 3/22/2016 11:10:03 AM
Mologen AG (MOLGF.PK) Appoints Walter Miller As New CFO 3/16/2016 10:37:18 AM
Mologen AG (MOLGF.PK): Extension Of TEACH Study Based On Supportive First Study Results 3/14/2016 11:10:08 AM